Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2023
The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. From 1 January 2023 to 31 December 2023, a total of 57 hospitals across Australia participated in the Australian Gram-negative Surveillance Outcome Program (GnSOP). The 2023 survey tested 10,453 isolates, comprising <i>Enterobacterales</i> (9,503; 90.9%), <i>P. aeruginosa</i> (806; 7.7%) and <i>Acinetobacter</i> species (144; 1.4%), using commercial automated methods. The results were analysed using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2024). Key resistances reported are to the third-generation cephalosporin ceftriaxone in 12.9% of <i>Escherichia coli</i> and in 6.9% of <i>Klebsiella pneumoniae</i> complex isolates. Resistance rates to ciprofloxacin were 14.5% for <i>E. coli</i>; 7.8% for the <i>K. pneumoniae</i> complex; 3.2% for the <i>Enterobacter cloacae</i> complex; and 7.6% for <i>P. aeruginosa</i>. Resistance rates to piperacillin-tazobactam were 6.0%; 9.4%; 23.3%; and 13.7% for the same four species/complexes, respectively. Thirty <i>Enterobacterales</i> isolates from 30 patients were shown to harbour a carbapenemase gene: ten with a <i>bla</i><sub>NDM</sub> gene (<i>bla</i><sub>NDM-1</sub> [4], <i>bla</i><sub>NDM-5</sub> [4], <i>bla</i><sub>NDM-7</sub> [2]); nine with a <i>bla</i><sub>OXA-48</sub>-like gene (<i>bla</i><sub>OXA-244</sub> [4], <i>bla</i><sub>OXA-48</sub> [2], <i>bla</i><sub>OXA-181</sub> [1], <i>bla</i><sub>OXA-232</sub> [1], <i>bla</i><sub>OXA-484</sub> [1]); eight with <i>bla</i><sub>IMP-4</sub>; two with <i>bla</i><sub>NDM-5</sub> + a <i>bla</i><sub>OXA-181</sub>-like gene; and one with <i>bla</i><sub>KPC-2</sub> + <i>bla</i><sub>NDM-5</sub> + <i>bla</i><sub>OXA-181</sub>. Transmissible carbapenemase genes were also detected in two <i>Acinetobacter baumannii</i> complex isolates (<i>bla</i><sub>OXA-23</sub>; <i>bla</i><sub>OXA-23</sub> + <i>bla</i><sub>OXA-58</sub> + <i>bla</i><sub>IMP-4</sub>) and one <i>P. aeruginosa</i> (<i>bla</i><sub>IMP-4</sub>).
Authors
- Alicia Fajardo Lubián (ORCID: https://orcid.org/0000-0002-9537-4878)
- Thomas Gottlieb (ORCID: https://orcid.org/0000-0002-7856-5517)
- Geoffrey W. Coombs (ORCID: https://orcid.org/0000-0003-1635-6506)
- Jonathan R. Iredell (ORCID: https://orcid.org/0000-0003-2469-7060)
- Sally R. Partridge (ORCID: https://orcid.org/0000-0002-0666-8330)
- Jan Bell (ORCID: https://orcid.org/0000-0002-4298-7267)
- Jennifer Robson (ORCID: https://orcid.org/0000-0001-7207-244X)
- Denise A Daley
Institutions
- Australian Institute of Criminology (AU)
- The University of Sydney (AU)
- Murdoch University (AU)
- Concord Repatriation General Hospital (AU)
- Fiona Stanley Hospital (AU)
- Westmead Hospital (AU)
- Westmead Institute for Medical Research (AU)
- Sullivan Nicolaides Pathology (AU)
Publication Details
- Journal
- Communicable Diseases Intelligence
- Published
- 2025-02-18
- DOI
- https://doi.org/10.33321/cdi.2025.49.003
- Citations
- 2
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.18
Funders
- Australian Government
- Department of Health and Aged Care, Australian Government